Valuation : Scholar Rock Holding Corporation

Market Cap 7.04B 6.07B 5.69B 5.19B 9.78B 673B 9.81B 67.47B 26.33B 340B 26.43B 25.85B 1,126B P/E 2026 *
-17.8x
P/E 2027 * -22.5x
Enterprise Value 6.72B 5.79B 5.43B 4.96B 9.34B 642B 9.37B 64.43B 25.14B 324B 25.24B 24.69B 1,075B EV / Sales 2026 *
1,183x
EV / Sales 2027 * 45.4x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day-2.46%
1 week+2.30%
Current month+22.21%
1 month+17.81%
3 months+17.24%
6 months+30.56%
Current year+31.21%
1 week 55.9
Extreme 55.9
61.76
1 month 45.73
Extreme 45.73
61.76
Current year 38.75
Extreme 38.75
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 5.94
Extreme 5.94
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 27/04/2025
Director of Finance/CFO 62 27/04/2025
Chief Operating Officer 58 27/04/2025
Director TitleAgeSince
Chairman 59 01/07/2017
Director/Board Member 53 01/08/2014
Director/Board Member 78 01/10/2016
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Sell

Director

-2,544 0.0022%
1/7/26 Sell

Director

-5,446 0.0047%
1/7/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%+2.30%+77.03%+850.66% 7.04B
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -2.07%-1.50%+59.70%+257.43% 28.9B
Weighted average by Cap. -1.94%-1.41%+54.30%+168.54%

Financials

2026 *2027 *
Net sales 5.68M 4.9M 4.59M 4.19M 7.9M 543M 7.92M 54.48M 21.26M 274M 21.34M 20.88M 909M 146M 126M 118M 108M 203M 13.97B 204M 1.4B 547M 7.05B 549M 537M 23.38B
Net income -425M -367M -344M -314M -591M -40.65B -593M -4.08B -1.59B -20.52B -1.6B -1.56B -68.04B -364M -314M -294M -268M -505M -34.77B -507M -3.49B -1.36B -17.55B -1.37B -1.34B -58.2B
Net Debt -317M -273M -256M -234M -441M -30.31B -442M -3.04B -1.19B -15.3B -1.19B -1.16B -50.74B -405M -349M -327M -299M -563M -38.7B -564M -3.88B -1.51B -19.53B -1.52B -1.49B -64.77B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
28/08/26 USD 57.80 -2.46% 809,724
27/08/26 USD 59.26 -1.30% 620,744
26/08/26 USD 60.04 +3.07% 2,281,289
25/08/26 USD 58.25 +0.09% 1,209,520
24/08/26 USD 58.20 +3.01% 1,222,246
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
57.80USD
Average target price
60.75USD
Spread / Average Target
+5.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock